Skip to content

Cartesian Therapeutics, Inc.

RNAC· NasdaqCore metricsCIK 1453687

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -7.08%
Market cap
$194.30M
30.5M shares
Filings
877
$0.00
Q3 2026−92.8% FY25 yoy
-$11.47M
Q3 2026N/M FY25 yoy
-$25.00M
Q3 2026N/M FY25 yoy
-$71.69M
Q3 2026derivedN/M FY25 yoy
-$0.38
Q3 2026N/M FY25 yoy
$122.98M
Q3 2026−41.1% FY25 yoy
$194.30M
—
81.1×
—
-46.26%
—

Twelve months to Sep 30, 2026 · derived

Price

$6.3712.74%$0.93past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.80MFY 2025
$110.78M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$2,797,000reported
FY 20242024-12-31$38,913,000reported
FY 20232023-12-31$26,004,000reported
FY 20222022-12-31$110,777,000reported
FY 20212021-12-31$85,077,000reported
FY 20202020-12-31$16,597,000reported
FY 20192019-12-31$6,677,000reported
FY 20182018-12-31$903,000reported
FY 20172017-12-31$207,000reported
FY 20162016-12-31$8,083,000reported
FY 20152015-12-31$6,011,000reported
FY 20142014-12-31$3,040,000reported

Segments

Segments
Revenue by Segments, FY2023 to FY2025FY2023Reporting Segments · FY2023 · $26.00MFY2024Operating Segment · FY2024 · $38.28MReporting Segments · FY2024 · $38.28MFY2025Operating Segment · FY2025 · $400.00K
LineFY2025ShareChange
Operating Segment$400.00K100%−99.0%
Reporting Segments———
Total$400.00K

From the 10-K filed Mar 9, 2026RNAC

Pharmaceutical preparations

Cartesian Therapeutics, Inc. is the 197th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Cartesian Therapeutics, Inc. · CIK 1453687 · Engraved from SEC EDGAR